Financials Roche Holding AG OTC Markets

Equities

RHHBY

US7711951043

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
35.57 ^USD	-0.39%		+1.69%	-1.82%

06-25	Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval	MT
06-25	Roche: approval of Ocrevus SC in Europe	CF

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	267,779	264,244	306,810	259,166	197,073	204,624	-	-
Enterprise Value (EV) ¹	270,284	266,126	324,977	274,750	215,772	218,713	213,626	207,655
P/E ratio	20.1 x	18.7 x	23.4 x	18.9 x	17.1 x	14.9 x	13.5 x	12.5 x
Yield	2.87%	2.94%	2.45%	3.27%	3.93%	3.86%	3.97%	4.07%
Capitalization / Revenue	4.36 x	4.53 x	4.89 x	4.1 x	3.36 x	3.38 x	3.2 x	3.07 x
EV / Revenue	4.4 x	4.56 x	5.17 x	4.34 x	3.67 x	3.61 x	3.34 x	3.11 x
EV / EBITDA	10.6 x	11 x	13.2 x	11 x	9.82 x	9.59 x	8.68 x	8.03 x
EV / FCF	16.1 x	24.3 x	20.7 x	21.1 x	19.1 x	16.2 x	14.5 x	13.5 x
FCF Yield	6.2%	4.11%	4.83%	4.75%	5.23%	6.17%	6.88%	7.41%
Price to Book	8.28 x	7.27 x	13.2 x	8.29 x	5.91 x	5.76 x	4.82 x	4.07 x
Nbr of stocks (in thousands)	856,061	854,642	800,952	854,579	798,652	797,242	-	-
Reference price ²	314.0	309.0	379.1	290.5	244.5	253.4	253.4	253.4
Announcement Date	30/01/20	04/02/21	03/02/22	02/02/23	01/02/24	-	-	-

¹CHF in Million²CHF

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	61,466	58,323	62,801	63,281	58,716	60,610	63,999	66,718
EBITDA ¹	25,419	24,281	24,692	25,015	21,976	22,813	24,607	25,859
EBIT ¹	22,479	21,536	21,897	22,173	19,240	20,129	21,875	22,970
Operating Margin	36.57%	36.93%	34.87%	35.04%	32.77%	33.21%	34.18%	34.43%
Earnings before Tax (EBT) ¹	16,614	17,965	17,398	16,327	14,079	17,746	19,651	20,829
Net income ¹	13,497	14,295	13,930	12,421	11,498	13,251	14,757	15,789
Net margin	21.96%	24.51%	22.18%	19.63%	19.58%	21.86%	23.06%	23.66%
EPS ²	15.62	16.52	16.20	15.37	14.31	16.96	18.79	20.31
Free Cash Flow ¹	16,764	10,943	15,691	13,041	11,288	13,500	14,699	15,387
FCF margin	27.27%	18.76%	24.99%	20.61%	19.22%	22.27%	22.97%	23.06%
FCF Conversion (EBITDA)	65.95%	45.07%	63.55%	52.13%	51.37%	59.18%	59.74%	59.5%
FCF Conversion (Net income)	124.21%	76.55%	112.64%	104.99%	98.17%	101.88%	99.61%	97.46%
Dividend per Share ²	9.000	9.100	9.300	9.500	9.600	9.787	10.06	10.32
Announcement Date	30/01/20	04/02/21	03/02/22	02/02/23	01/02/24	-	-	-

¹CHF in Million²CHF

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2019 S2	2020 S1	2020 S2	2021 S1	2021 Q3	2021 Q4	2021 S2	2022 Q1	2022 Q2	2022 S1	2022 Q3	2022 Q4	2022 S2	2023 Q1	2023 Q2	2023 S1	2023 Q3	2023 S2	2024 Q1	2024 Q2	2024 S1	2024 Q3	2024 Q4	2024 S2	2025 Q1	2025 S1	2025 S2
Net sales ¹	30,997	29,281	29,042	30,713	15,971	16,117	32,088	16,445	15,850	32,295	14,742	16,244	30,986	15,322	14,457	29,779	14,274	28,937	14,399	14,540	29,770	14,690	15,015	30,770	15,320	30,630	30,615
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT	10,116	11,766	9,770	11,652	-	-	10,245	-	-	12,668	-	-	9,505	-	-	10,911	-	8,329	-	-	10,770	-	-	9,625	-	-	-
Operating Margin	32.64%	40.18%	33.64%	37.94%	-	-	31.93%	-	-	39.23%	-	-	30.68%	-	-	36.64%	-	28.78%	-	-	36.18%	-	-	31.28%	-	-	-
Earnings before Tax (EBT)	6,260	10,181	7,784	9,887	-	-	7,511	-	-	10,985	-	-	5,342	-	-	9,174	-	4,905	-	-	-	-	-	-	-	-	-
Net income	4,878	8,079	6,216	7,803	-	-	6,127	-	-	8,530	-	-	3,891	-	-	7,137	-	4,361	-	-	-	-	-	-	-	-	-
Net margin	15.74%	27.59%	21.4%	25.41%	-	-	19.09%	-	-	26.41%	-	-	12.56%	-	-	23.97%	-	15.07%	-	-	-	-	-	-	-	-	-
EPS	5.630	9.320	7.200	9.050	-	-	7.150	-	-	10.54	-	-	4.830	-	-	8.870	-	5.440	-	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	30/01/20	23/07/20	04/02/21	22/07/21	20/10/21	03/02/22	03/02/22	25/04/22	21/07/22	21/07/22	18/10/22	02/02/23	02/02/23	27/04/23	27/07/23	27/07/23	01/11/23	01/02/24	-	-	-	-	-	-	-	-	-

¹CHF in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	2,505	1,882	18,167	15,584	18,699	14,089	9,002	3,031
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	0.0985 x	0.0775 x	0.7357 x	0.623 x	0.8509 x	0.6176 x	0.3658 x	0.1172 x
Free Cash Flow ¹	16,764	10,943	15,691	13,041	11,288	13,500	14,699	15,387
ROE (net income / shareholders' equity)	57.7%	48%	56%	62.5%	45.7%	43.7%	40.5%	36.4%
ROA (Net income/ Total Assets)	21.6%	19.6%	19.1%	18.2%	16.7%	14.6%	14.9%	14.7%
Assets ¹	62,621	72,966	72,951	68,337	68,793	90,910	98,817	107,716
Book Value Per Share ²	37.90	42.50	28.80	35.00	41.40	44.00	52.60	62.30
Cash Flow per Share ²	25.90	21.50	24.40	22.80	20.00	20.10	21.50	23.70
Capex ¹	3,503	3,528	3,693	3,449	3,742	3,742	3,922	4,083
Capex / Sales	5.7%	6.05%	5.88%	5.45%	6.37%	6.17%	6.13%	6.12%
Announcement Date	30/01/20	04/02/21	03/02/22	02/02/23	01/02/24	-	-	-

¹CHF in Million²CHF

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

253.4 CHF

Average target price

278.1 CHF

Spread / Average Target

+9.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+45.05%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+18.79%	247B
NOVARTIS AG	+13.57%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B
SANOFI	+1.05%	122B

Other Pharmaceuticals